Endexo™ surface modifying macromolecules enhance the biocompatibility of medical devices that come in contact with blood, tissue, or other biological fluids. They are low molecular weight fluoro-oligomeric additives that migrate to the top few nanometers of the device surface, during the manufacturing process.
In the presence of blood, the modified surfaces are able to suppress procoagulant protein conformation, reduce platelet adhesion and inhibit platelet activation. In the presence of bacteria mediated fluids, the modified surfaces are effective at reducing bacteria adhesion (up to 5 log CFU) and encrustation. Altogether, the effect is reduced biofouling, which can help to reduce thrombosis, infection or inflammation without the use of drugs.
Endexo™ platform technology has broad applicability. With a myriad of formulations, Endexo technology can be used with a variety of base polymers (including polyurethane, polysulfone, PVC, polypropylene, and silicone) and manufacturing techniques (such as melt extrusion, solution spinning, injection molding). The Endexo™ molecules become an integral part of the base material providing durable surface modification and extended efficacy of treatment compared to traditional coatings.
Average reduction across 8500 BioFlo PICCs studied:
As reported by AngioDynamics
Blood Contacting Devices
Dialyzers (licensed exclusively to Fresenius Medical Care)
Dialysis blood lines (licensed exclusively to Fresenius Medical Care)
Non-dialysis blood lines
Medical Device Anti-fouling
Reduced protein adhesion
Reduced bacterial adhesion